In conclusion, our study is, to the best of our knowledge, the first study that longitudinally assessed sTK1 as a putative long-term prognosticator in HER2 + breast cancer, both at baseline and following short-term exposure to neoadjuvant HER2-targeted therapy. Here, ERBB2 is linked to breast cancer.